Valuation : Nanobiotix

Market Cap 1.96B 2.28B 1.83B 1.68B 3.16B 218B 3.17B 21.7B 8.48B 110B 8.56B 8.38B 363B P/E 2026 *
-94x
P/E 2027 * -163x
Enterprise Value 2B 2.33B 1.88B 1.72B 3.24B 223B 3.24B 22.21B 8.68B 112B 8.76B 8.57B 372B EV / Sales 2026 *
52.6x
EV / Sales 2027 * 47.5x
Free-Float
88.26%
Yield 2026 *
-
Yield 2027 * -
1 day+11.43%
1 week+1.26%
Current month+14.47%
1 month+10.16%
3 months+9.16%
6 months+68.19%
Current year+97.95%
1 week 33.7
Extreme 33.7
38.8
1 month 31.94
Extreme 31.94
39.98
Current year 16.66
Extreme 16.66
47.66
1 year 6.96
Extreme 6.96
47.66
3 years 2.62
Extreme 2.62
47.66
5 years 1.61
Extreme 1.612
47.66
10 years 1.61
Extreme 1.612
47.66
Manager TitleAgeSince
Chief Executive Officer 55 2009-11-15
Director of Finance/CFO 54 2021-05-31
Chief Tech/Sci/R&D Officer 68 2023-09-04
Director TitleAgeSince
Director/Board Member 76 2011-06-22
Director/Board Member 65 2013-12-31
Director/Board Member 57 2014-06-17
Date Insider Type Main position Quantity % Market Cap.
7/17/26 Buy

Chairman

598 0.0012%
7/17/26 Buy

Chairman

598 0.0012%
7/16/26 Buy

Chairman

6,114 0.0121%
Change 5-day change 1-year change 3-year change Capi.($)
+11.43%+1.26%+424.46%+293.88% 2.05B
+0.10%+0.44%+2.80%+23.74% 50.96B
+1.65%+4.05%+479.15%+582.92% 46.18B
-0.91%+1.03%+24.27%+84.56% 42.73B
+0.31%+2.48%+38.98%+18.31% 43.04B
-2.27%-3.02%+14.22%+51.50% 33.48B
-1.25%+0.15%+29.59%+134.50% 17.28B
-0.33%-2.01% - - 16.43B
+0.25%+3.31%+11.38%+30.68% 14.73B
+0.44%+2.23%+83.02%+49.91% 14.09B
Average +1.22%+0.28%+123.10%+141.11% 28.1B
Weighted average by Cap. +0.22%+1.08%+106.51%+144.91%

Financials

2026 *2027 *
Net sales 38.06M 44.34M 35.63M 32.63M 61.47M 4.23B 61.64M 422M 165M 2.13B 166M 163M 7.06B 42.83M 49.89M 40.09M 36.71M 69.16M 4.76B 69.36M 475M 186M 2.4B 187M 183M 7.95B
Net income -12.18M -14.18M -11.4M -10.44M -19.66M -1.35B -19.72M -135M -52.77M -683M -53.26M -52.11M -2.26B -52.44K -61.09K -49.1K -44.96K -84.69K -5.83M -84.93K -581K -227K -2.94M -229K -224K -9.73M
Net Debt 46M 53.59M 43.07M 39.43M 74.29M 5.12B 74.5M 510M 199M 2.58B 201M 197M 8.54B 76.4M 89.01M 71.53M 65.5M 123M 8.5B 124M 847M 331M 4.28B 334M 327M 14.18B
Logo Nanobiotix
Nanobiotix is a pioneer and leader in nanomedicine that has developed a revolutionary approach to the treatment of cancer. The company focuses its effort on the development of its products portfolio entirely patented, NanoXray, innovation based on the physical mode of action of nanoparticles that, under the action of radiation, allow maximizing the absorption of X-rays inside the cancer cells without increasing the dose received by the surrounding healthy tissue. NanoXray products are compatible with standard radiotherapy treatments and are intended to potentially treat a wide variety of cancers via multiple routes of administration. The company's resources are primarily devoted to the development of its lead product candidate: JNJ-1900 (NBTXR3), which is the product of its proprietary oncology platform and has already achieved market authorization in Europe for the treatment of patients with soft tissue sarcoma under.
Employees
100
Date Price Change Volume
26-08-27 38.60 +11.43% 277,870
26-08-26 €34.64 -3.08% 92,032
26-08-25 €35.74 +4.69% 110,603
26-08-24 €34.14 -10.25% 229,574
26-08-21 €38.04 +1.71% 76,355
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
38.60EUR
Average target price
52.20EUR
Spread / Average Target
+35.23%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NANO Stock